| Name | Caffeine + Ergotamine Tartrate |
| Classes |
Analgesic / Pain Killer Central Nervous System Agent Antimigraine Agent |
| Diseases |
CNS Disorder Migraine |
Bangla
EnglishCaffeine + Ergotamine Tartrate
Caffeine + Ergotamine Tartrate is a combination drug classified as an ergot alkaloid and stimulant. Ergotamine acts as a vasoconstrictor, constricting blood vessels in the brain and relieving the symptoms of migraine headaches. Caffeine enhances the vasoconstrictive effects of ergotamine and may also help alleviate headache symptoms by increasing blood flow.
- Caffeine + Ergotamine Tartrate is indicated for the acute treatment of migraine headaches with or without aura.
- It is not recommended for prophylactic or daily use, as it may lead to medication overuse headaches.
- For best results, dosage should start at the first sign of an attack.
- One suppository at start of attack; second suppository after 1 hour, if needed for full relief.
- Two suppositories is the maximum dose for an individual attack.
- Total weekly dosage should not exceed 5 suppositories. Ergotamine tartrate and caffeine suppositories should not be used for chronic daily administration.
- Cardiovascular: Vasoconstrictive complications of a serious nature may occur at times. These include ischemia, cyanosis, absence of pulse, cold extremities, gangrene, precordial distress and pain, EKG changes and muscle pains. Although these effects occur most commonly with long-term therapy at relatively high doses, they have also been reported with short-term or normal doses. Other cardiovascular adverse effects include transient tachycardia or bradycardia and hypertension.
- Gastrointestinal: Nausea and vomiting; rectal or anal ulcer (from overuse of suppositories).
- Neurological: paresthesias, numbness, weakness, and vertigo. Allergic: Localized edema and itching.
- Fibrotic Complications
- Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of Caffeine + Ergotamine Tartrate with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP 3A4 inhibition elevates the serum levels of Caffeine + Ergotamine Tartrate, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated.
- There have been a few reports of patients on Caffeine + Ergotamine Tartrate (ergotamine tartrate and caffeine) therapy developing retroperitoneal and/or pleuropulmonary fibrosis. There have also been rare reports of fibrotic thickening of the aortic, mitral, tricuspid, and/or pulmonary valves with long-term continuous use of Caffeine + Ergotamine Tartrate
- Caffeine + Ergotamine Tartrate (ergotamine tartrate and caffeine) should not be administered with other vasoconstrictors. Use with sympathomimetics (pressor agents) may cause extreme elevation of blood pressure. The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of Caffeine + Ergotamine Tartrate (ergotamine tartrate and caffeine) by blocking the vasodilating property of epinephrine. Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.
- Caffeine + Ergotamine Tartrate (ergotamine tartrate and caffeine) is contraindicated in labor and delivery due to its oxytocic effect which is maximal in the third trimester.
Contraindication
Caffeine + Ergotamine Tartrate is contraindicated in-
- Hypersensitivity to any of the components.
- Coadministration of ergotamine with potent CYP 3A4 inhibitors such as-
None known.
Caffeine + Ergotamine Tartrate is contraindicated in the following conditions-
- Women who are or may become pregnant
- Peripheral vascular disease, coronary heart disease, hypertension, impaired hepatic or renal function and sepsis.
